Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL550499 | 1.00 | HSD11B1 (0.40) | HSD11B1HRH3ADORA2A | |
| SCHEMBL549589 | 1.00 | HSD11B1 (0.40) | HSD11B1HRH3ADORA2A | |
| SCHEMBL549590 | 1.00 | HSD11B1 (0.40) | HSD11B1HRH3ADORA2A | |
| SCHEMBL2699043 | 1.00 | HSD11B1 (0.40) | HSD11B1HRH3ADORA2A | |
| SCHEMBL2699046 | 1.00 | HSD11B1 (0.40) | HSD11B1HRH3ADORA2A | |
| SCHEMBL550504 | 1.00 | HSD11B1 (0.40) | HSD11B1HRH3ADORA2A | |
| SCHEMBL550546 | 1.00 | HSD11B1 (0.40) | HSD11B1HRH3ADORA2A | |
| SCHEMBL4570200 | 1.00 | HSD11B1 (0.40) | HSD11B1HRH3ADORA2A | |
| Hydrochloric Acid SCHEMBL549548 | 0.99 | HSD11B1 (0.39) | HSD11B1HRH3ADORA2A | |
| Hydrochloric Acid SCHEMBL549375 | 0.99 | HSD11B1 (0.39) | HSD11B1HRH3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| CN-111454188-A | Cyclopropylamines as L SD1inhibitors | 因赛特公司 | 2020-07-28 | — | — | CN | disclosed |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-07-21 | — | — | US | disclosed |
| EP-3626713-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-106164066-B | Cyclopropylamines as LSD1inhibitors | 因赛特公司 | 2020-01-17 | — | — | CN | disclosed |
| EP-3105218-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORP (US) | 2019-09-25 | — | — | EP | disclosed |
| US-20190211014-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-07-11 | — | — | US | disclosed |
| US-10174030-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170342070-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-9670210-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| EP-2540723-A1 | Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 | Incyte Corporation (US) | 2013-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HSD11B1 1922/4885HRH3 473/4885ADORA2A 1863/4885 |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | HSD11B1 1922/4885HRH3 473/4885ADORA2A 1863/4885 |
| US-20170342070-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HSD11B1 1922/4885HRH3 473/4885ADORA2A 1863/4885 |
| US-20190211014-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HSD11B1 1922/4885HRH3 473/4885ADORA2A 1863/4885 |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | HSD11B1 1922/4885HRH3 473/4885ADORA2A 1863/4885 |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HSD11B1 1922/4885HRH3 473/4885ADORA2A 1863/4885 |
| US-10174030-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | HSD11B1 1922/4885HRH3 473/4885ADORA2A 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.